Inherited DNA-repair gene mutations in African American men with prostate cancer
Metrics: PDF 640 views | Full Text 868 views | ?
Oliver Sartor1, Shan Yang2, Elisa Ledet1, Marcus Moses1 and Piper Nicolosi2
1 Tulane Cancer Center, Tulane University of School of Medicine, New Orleans, Louisiana, United States
2 Invitae Corporation, Genetics, San Francisco, California, United States
Keywords: prostate cancer; DNA repair; BRCA; African American; ethnicity
Received: October 24, 2019 Accepted: January 04, 2020 Published: January 28, 2020
African American men with prostate cancer are understudied relative to Caucasians with prostate cancer with regard to testing for pathogenic germline DNA repair gene mutations. Herein we evaluate these two populations in a large commercial dataset and compare the detection of pathogenic/likely pathogenic alterations in 14 well annotated DNA repair genes (BRCA2, BRCA1, PALB2, ATM, RAD51C, CHEK2, PMS2, BARD1, BRIP1, MLH1, MSH2, MSH6, NBN, and RAD51D). Overall, pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians. Upon a more in-depth analysis, the risk of germline pathogenic/likely pathogenic BRCA mutations was similar between the two populations whereas there was a lower risk among African Americans for the non-BRCA mutations. No African American men were noted to have mutations in BARD1, BRIP1, MLH1, MSH2, MSH6, NBN, and RAD51D in this data set. Stage, grade, and metastatic status were not assessed in this group of patients. Larger and more detailed studies conducted in men with prostate cancer are required to confirm these findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.